News

January 14, 2019

Researchers Create Dressing Glove for EB Based on Patients’ Feedback

News

King’s College London researchers created a new type of dressing glove for those with epidermolysis bullosa (EB), based on patients’ feedback. The glove was designed to adapt to patients’ hands, keeping fingers ... Read more

January 11, 2019

Diagnostic Testing More Common in Most Severe EB Types, Study Reports

News

Diagnostic testing in patients with epidermolysis bullosa (EB) is more frequent in the most severe disease types, according to a large study in North America. The findings also revealed ... Read more

January 7, 2019

Collagen XVII Mutation Behind Skin Blistering Seen in Mild JEB, Study Confirms

News

The collagen XVII mutation p.R1303Q that causes late-onset, mild junctional epidermolysis bullosa (JEB) is characterized by a weaker collagen XVII connection to another adhesion molecule in the skin, called laminin-332, ... Read more

January 2, 2019January 2, 2019

Four Patients Treated in Phase 2 Trial Testing Topical Gene Therapy, KB103, for Wound Healing

News

All four patients with dystrophic epidermolysis bullosa (DEB) enrolled in a Phase 2 study testing the safety and efficacy of Krystal Biotech’s topical gene therapy candidate KB103 have received the treatment. Results ... Read more

December 20, 2018December 20, 2018

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

News

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to ... Read more

December 17, 2018December 17, 2018

EB Groups Give Fibrocell $900,000 to Advance Gene Therapy in Clinical Trials

News

The EB Research Partnership (EBRP) and Epidermolysis Bullosa Medical Research Foundation (EBMRF) granted $900,000 to Fibrocell, a gene therapy company, to support the clinical development of FCX-007 to possibly ... Read more

December 10, 2018December 10, 2018

Phase 3 Trial of RDEB Therapy EB-101 to Start in 2019, Abeona Therapeutics Says

News

Abeona Therapeutics plans to start a Phase 3 trial in 2019 testing the cell therapy candidate EB-101 as a treatment for recessive dystrophic epidermolysis bullosa (RDEB). The multi-center, randomized study, ... Read more

December 3, 2018December 3, 2018

TXA127 Enters Development Program as Potential Treatment for EB

News

Constant Pharmaceuticals recently announced plans to begin a development program for TXA127 for the treatment of epidermolysis bullosa (EB). The potential therapy is expected to enter Phase 2 clinical ... Read more

November 26, 2018November 26, 2018

Diacerein Ointment Could Be Safe Treatment for Generalized Severe EBS, Study Suggests

News

A 1% diacerein ointment could be a safe and well-tolerated way to treat generalized severe epidermolysis bullosa simplex (EBS), according to a study involving two boys treated for four weeks. In ... Read more

November 12, 2018November 12, 2018

Intravenous Immunoglobulin and Rituximab Most Effective EBA Treatments, Study Reports

News

Treatment with intravenous immunoglobulin (IVIG) and off-label rituximab can lead to complete remission of epidermolysis bullosa acquisita (EBA), according to a study that also illustrates the variable clinical and immunological presentations ... Read more

Pin It on Pinterest